Although the overall mortality was not substantially influenced by the choice of SU, a subgroup analysis of patients with documented CAD showed a trend toward an increased overall mortality risk with glyburide vs. glimepiride and glipizide vs. glimepiride.
← all excerpts
Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel.
1
—
—